WYDASE INJECTION LIQ 150 UNITS/ML 150 UNIT
HYALURONIDASE : 150 UNIT · DIN 02041278 · WYETH-AYERST CANADA INC.
Health Canada status: CANCELLED POST MARKET
What is WYDASE INJECTION LIQ 150 UNITS/ML?
WYDASE INJECTION LIQ 150 UNITS/ML 150 UNIT contains HYALURONIDASE : 150 UNIT. It is listed in the Health Canada Drug Product Database under DIN 02041278, held by WYETH-AYERST CANADA INC., supplied as LIQUID for BLOCK/INFILTRATION ; SUBCUTANEOUS administration. Health Canada currently lists it as cancelled post market, status dated 10-Jun-2002. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is WYDASE INJECTION LIQ 150 UNITS/ML called?
The same molecule, HYALURONIDASE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Amphadase | Latin | Iceland |
| HYALASE | Latin | Bahrain |
| Hyaluronidase | Latin | Iceland |
| Hylenex | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02041278 |
|---|---|
| Brand name | WYDASE INJECTION LIQ 150 UNITS/ML |
| Generic / active ingredient | HYALURONIDASE : 150 UNIT |
| Manufacturer | WYETH-AYERST CANADA INC. |
| Strength | 150 UNIT |
| Dosage form | LIQUID |
| Route of administration | BLOCK/INFILTRATION ; SUBCUTANEOUS |
| Schedule | Schedule D |
| ATC code | B06AA03 HYALURONIDASE |
| AHFS class | 44:00.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 10-Jun-2002 |
| Original market date | 1994-12-31 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02041278 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2041278 |
| Brand name | WYDASE INJECTION LIQ 150 UNITS/ML |
| Active ingredient / INN | HYALURONIDASE : 150 UNIT |
| ATC code | B06AA03 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B06 |
| AHFS class | 44:00.00 |
| Health Canada schedule | Schedule D |
| Biosimilar biologic | No |
| Market authorization holder | WYETH-AYERST CANADA INC. |
Which pack is which?
| Strength on the label | 150 UNIT |
|---|---|
| Dosage form | LIQUID |
| Route | BLOCK/INFILTRATION ; SUBCUTANEOUS |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code B06AA03 HYALURONIDASE. 0 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| WYDASE INJ 150UNIT/ML | 150 UNIT | LIQUID | WYETH LTD. | CANCELLED POST MARKET | DIN 00036307 |
Who else supplies HYALURONIDASE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. HYALURONIDASE appears in 7 registered pack listings across 3 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does HYALURONIDASE cost around the world?
HYALURONIDASE is listed on 4 national price registers Nexara tracks, across 6 pack listings published on 4 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Iceland | max wholesale | 3 | 3 | 02 Sep 2026 |
| United Arab Emirates | public | 1 | 1 | 31 Aug 2026 |
| Bahrain | retail (max) | 1 | 1 | 01 Sep 2026 |
| United Kingdom | hospital | 1 | 1 | 31 Aug 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.